Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 8Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 112Neoplasms 73Carcinoma, Non-Small-Cell Lung 36Carcinoma, Renal Cell 35Prostatic Neoplasms 34Colorectal Neoplasms 34Lung Neoplasms 31Melanoma 17Multiple Myeloma 16Ovarian Neoplasms 13Urinary Bladder Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 11Lymphoma, Follicular 11Colonic Neoplasms 11Stomach Neoplasms 10Lymphoma 10Kidney Neoplasms 10Hematologic Neoplasms 10Rectal Neoplasms 9Arthritis, Rheumatoid 9Recurrence 8Papillomavirus Infections 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Pancreatic Neoplasms 7Neoplasms, Plasma Cell 7Lymphoma, Large B-Cell, Diffuse 7COVID-19 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Has results × Urothelial Cancer × Clear all
NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡